Lewisville, Texas-based orthopedic device company Orthofix Medical, Inc. has announced the appointment of Thomas A. West to both its Board of Directors and Compensation and Talent Development Committee. West, current president, director, and CEO of drug-device company Intersect ENT, brings over 30 years of experience to the role. Before his role at Intersect ENT, West was president of the Diagnostic Solutions Division at Hologic, Inc. He also previously worked in pharmaceuticals and medical device sectors at Johnson & Johnson for 23 years.
Orthofix Appoints Thomas A. West to BOD
1 min read Premium comments
Secondary#orthofixmedical#thomaswest
West holds degrees from Princeton University and the Wharton School of the University of Pennsylvania. He also sits on the Board of Directors for the Advanced Medical Technology Association (AdvaMed). In his current leadership role at Intersect ENT, West was at the helm of an acquisition agreement with Medtronic for $1.1 billion in August 2021.
“Tom joins the Orthofix Board of Directors with more than 30 years of global experience in the medical device industry,” said Chair of the Board Catherine Burzik. “We feel his vast experience will benefit Orthofix by providing international and domestic insights and guidance as we grow globally. We are very pleased he has chosen to join our Board.”
Originally founded in Verona, Italy in 1980, Orthofix has evolved and grown to become one of the leading medical ortho and spine device companies. The company aims to support health care providers in improving patient mobility and quality of life. Orthofix provides minimally invasive technology for bone, joint and spine care, including products to support pediatric ortho care, trauma and fracture care, limb reconstruction and foot and ankle issues. In addition, Orthofix prioritizes and supports humanitarian efforts such as Donate Life America, Support for Trusted World, Veterans Coalition of North Central Texas, Carter BloodCare and Donate Spine Fixation, which provides deformity correction products to impoverished children internationally via the World Pediatric Project.
Orthofix sells and distributes products globally, serving over 60 countries and employs over 1,000 people.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.